Moreover, E-X PPI2, E-X AS7, and panobinostat (a HDAC inhibitor) have been reported to silence ERCC1 and ACTL6A expressions in melanoma and ovarian/lung cancers, respectively, via in vitro and preclinical experiments (Xiao et al., 2021; McNeil et al., 2015). Here, ACTL6A is linked to lung cancer.